WallStSmart

EXACT Sciences Corporation (EXAS)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 1272% more annual revenue ($44.56B vs $3.25B). TMO leads profitability with a 15.0% profit margin vs -6.4%. TMO earns a higher WallStSmart Score of 59/100 (C).

EXAS

Avoid

32

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 5.3
Piotroski: 4/9Altman Z: 0.01

TMO

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EXAS.

TMOSignificantly Overvalued (-27.5%)

Margin of Safety

-27.5%

Fair Value

$384.82

Current Price

$490.77

$105.95 premium

UndervaluedFair: $384.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EXAS1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
23.1%8/10

Revenue surging 23.1% year-over-year

TMO3 strengths · Avg: 8.3/10
Market CapQuality
$182.14B9/10

Large-cap with strong market position

Operating MarginProfitability
21.2%8/10

Strong operational efficiency at 21.2%

Free Cash FlowQuality
$2.99B8/10

Generating 3.0B in free cash flow

Areas to Watch

EXAS4 concerns · Avg: 3.0/10
Price/BookValuation
8.3x4/10

Trading at 8.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-8.7%2/10

ROE of -8.7% — below average capital efficiency

Altman Z-ScoreHealth
0.012/10

Distress zone — elevated risk

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

P/E RatioValuation
27.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : EXAS

The strongest argument for EXAS centers on Revenue Growth. Revenue growth of 23.1% demonstrates continued momentum.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : EXAS

The primary concerns for EXAS are Price/Book, EPS Growth, Return on Equity.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

EXAS profiles as a growth stock while TMO is a value play — different risk/reward profiles.

EXAS carries more volatility with a beta of 1.44 — expect wider price swings.

EXAS is growing revenue faster at 23.1% — sustainability is the question.

TMO generates stronger free cash flow (3.0B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (59/100 vs 32/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

EXACT Sciences Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Exact Sciences Corporation offers cancer screening and diagnostic test products in the United States and internationally. The company is headquartered in Madison, Wisconsin.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?